Keywords
How to Cite
Abstract
This study examines promising strategies in the development of new therapies for the treatment of glaucoma, adopting an integrative and innovative perspective. Initially, advances in pharmacological therapies are highlighted, focusing on potential neuroprotective agents and specific modulators that have demonstrated efficacy in preserving ocular function and reducing disease progression.
Beyond pharmacological approaches, the analysis extends to consider interventions exploring the underlying mechanisms of glaucoma. The identification of molecular targets and emerging biological pathways emphasizes the importance of understanding the pathophysiology of the disease for the development of more targeted therapies.
Another notable point addresses complementary therapies, such as optimizing drug delivery strategies to improve effectiveness and reduce adverse effects. The analysis includes discussions on extended-release systems, innovative formulations, and minimally invasive surgical approaches, representing significant advancements in the quest for more effective and tolerable treatments.
Simultaneously, therapies aiming not only at reducing intraocular pressure but also at preserving and regenerating damaged ocular tissue are considered. This involves the exploration of regenerative approaches, such as cellular therapies and growth factors, highlighting their promising contribution to the restoration of ocular health.
In addition to therapeutic innovations, this work underscores the need for a comprehensive understanding of glaucoma, including genetic, metabolic, and environmental factors influencing individual responses to proposed therapies. Emphasizing the personalization of interventions highlights the complexity of the disease and the importance of considering individual patient characteristics.
In conclusion, the study emphasizes the importance of a multidisciplinary approach, integrating different therapeutic modalities to optimize outcomes in glaucoma treatment. The combination of innovative pharmacological approaches, advanced delivery strategies, and regenerative therapies emerges as a promising perspective to comprehensively and effectively address this ophthalmologic challenge.
References
Ahmed, I. I. K. et al. Subconjunctival filtration in evolution: current evidence on MicroShunt implantation for treating patients with glaucoma. Eye and Vision, v. 10, n. 10, 2023.
Baghban, R. et al. Recent advancements in nanomaterial-laden contact lenses for diagnosis and treatment of glaucoma: review and update. Journal of Nanobiotechnology, v. 21, p. 402, 2023.
Burgos-Blasco, B. et al. Evaluation of a Novel Ab Externo MicroShunt for the Treatment of Glaucoma. Adv Ther, v. 39, p. 3916–3932, 2022.
Chan, L. et al. New Devices in Glaucoma. Ophthalmol Ther, v. 12, p. 2381–2395, 2023.
Khodeiry, M. M. et al. Clinical Outcomes of Slow-Coagulation Continuous-Wave Transscleral Cyclophotocoagulation Laser for Treatment of Glaucoma. Curr Opin Ophthalmol, v. 33, n. 3, p. 237–242, 2022.
Radcliffe, N. The case for standalone micro-invasive glaucoma surgery: rethinking the role of surgery in the glaucoma treatment paradigm. v. 34, n. 2, 2023.
Sulak, R., Liu, X., Smedowski, A. The concept of gene therapy for glaucoma: the dream that has not come true yet. Neural Regen Res, v. 19, n. 1, 2024.
Tanihara, H. et al. Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine. Adv Ther, v. 40, p. 3559–3573, 2023.
Thomas, N. M., Nagrale, P. Rho Kinase Inhibitors as a Neuroprotective Pharmacological Intervention for the Treatment of Glaucoma. Cureus, 14(8): e28445, 2022.
Wang, J., Wang, H., Dang, Y. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy. Ophthalmol Ther, v. 12, p. 2943–2957, 2023.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Cibely Nascimento Arçari, Jordana Nascimento Arçari